Martin John Barron

Martin John Barron

Auto-generated profile, based on publicly available information

Martin John Barron

Faculty of Life Sciences and School of Dentistry, Manchester Academic Health Sciences Centre, University of Manchester, Manchester, UK

Research Focus & Metrics

Academic Career Length

32Years (1995-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2003 in Journal of Clinical Investigation
Verified
Journal Article
Closed access
PDF file
RTRobert W. Taylor
Robert W. Taylor
MBMartin J. Barron
Martin J. Barron
GBGillian M. Borthwick
Gillian M. Borthwick
AGAmy Gospel
Amy Gospel
PCPatrick F. Chinnery
Patrick F. Chinnery
DTDouglass M. Turnbull
Douglass M. Turnbull
The mitochondrial genome encodes 13 essential subunits of the respiratory chain and has remarkable genetics based on uniparental inheritance. Within human populations, the mitochondrial genome has a high rate of sequence divergence with multiple polymorphic variants and thus has played a major role in examining the evolutionary history of our species. In recent years it has also become apparent that pathogenic mitochondrial DNA (mtDNA) mutations play an important role in neurological and other diseases. Patients harbor many different mtDNA mutations, some of which are mtDNA mutations, some of which are inherited, but others that seem to be sporadic. It has also been suggested that mtDNA mutations play a role in aging and cancer, but the evidence for a causative role in these conditions is less clear. The accumulated data would suggest, however, that mtDNA mutations occur on a frequent basis. In this article we describe a new phenomenon: the accumulation of mtDNA mutations in human colonic crypt stem cells that result in a significant biochemical defect in their progeny. These studies have important consequences not only for understanding of the finding of mtDNA mutations in aging tissues and tumors, but also for determining the frequency of mtDNA mutations within a cell.

6 January 2006 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
LGLaura Greaves
Laura Greaves
SPSean L. Preston
Sean L. Preston
PTPaul J. Tadrous
Paul J. Tadrous
RTRobert W. Taylor
Robert W. Taylor
MBMartin J. Barron
Martin J. Barron
SMStuart A. C. McDonald
Stuart A. C. McDonald
The understanding of the fixation of mutations within human tissues and their subsequent clonal expansion is a considerable problem, of which little is known. We have previously shown that nononcogenic mutations in the mitochondrial genome occur in one of a number of morphologically normal colonic crypt stem cells, the progeny of which later occupy the whole crypt. We propose that these wholly mutated crypts then clonally expand by crypt fission, where each crypt divides into two mutated daughter crypts. Here we show that ( i ) mutated crypts in the process of fission share the same mutated mitochondrial genotype not present in neighboring cytochrome c oxidase-positive crypts (the odds of this being a random event are ≥2.48 × 10 9 :1); ( ii ) neighboring mutated crypts have the same genotype, which is different from adjacent cytochrome c oxidase-positive crypts; ( iii ) mutated crypts are clustered together throughout the colon; and ( iv ) patches of cytochrome c oxidase-deficient crypts increase in size with age. We thus demonstrate definitively that crypt fission is the mechanism by which mutations spread in the normal human colon. This has important implications for the biology of the normal adult human colon and possibly for the growth and spread of colorectal neoplasms.

20 November 2008 in Orphanet Journal of Rare Diseases
Verified
Journal Article
Open access
PDF file
MBMartin J Barron
Martin J Barron
SMSinead T McDonnell
Sinead T McDonnell
IMIain MacKie
Iain MacKie
MDMichael J Dixon
Michael J Dixon
The hereditary dentine disorders, dentinogenesis imperfecta (DGI) and dentine dysplasia (DD), comprise a group of autosomal dominant genetic conditions characterised by abnormal dentine structure affecting either the primary or both the primary and secondary dentitions. DGI is reported to have an incidence of 1 in 6,000 to 1 in 8,000, whereas that of DD type 1 is 1 in 100,000. Clinically, the teeth are discoloured and show structural defects such as bulbous crowns and small pulp chambers radiographically. The underlying defect of mineralisation often results in shearing of the overlying enamel leaving exposed weakened dentine which is prone to wear. Currently, three sub-types of DGI and two sub-types of DD are recognised but this categorisation may change when other causative mutations are found. DGI type I is inherited with osteogenesis imperfecta and recent genetic studies have shown that mutations in the genes encoding collagen type 1, COL1A1 and COL1A2, underlie this condition. All other forms of DGI and DD, except DD-1, appear to result from mutations in the gene encoding dentine sialophosphoprotein (DSPP), suggesting that these conditions are allelic. Diagnosis is based on family history, pedigree construction and detailed clinical examination, while genetic diagnosis may become useful in the future once sufficient disease-causing mutations have been discovered. Differential diagnoses include hypocalcified forms of amelogenesis imperfecta, congenital erythropoietic porphyria, conditions leading to early tooth loss (Kostmann's disease, cyclic neutropenia, Chediak-Hegashi syndrome, histiocytosis X, Papillon-Lefevre syndrome), permanent teeth discolouration due to tetracyclines, Vitamin D-dependent and vitamin D-resistant rickets. Treatment involves removal of sources of infection or pain, improvement of aesthetics and protection of the posterior teeth from wear. Beginning in infancy, treatment usually continues into adulthood with a number of options including the use of crowns, over-dentures and dental implants depending on the age of the patient and the condition of the dentition. Where diagnosis occurs early in life and treatment follows the outlined recommendations, good aesthetics and function can be obtained.

1 May 2011 in The American Journal of Human Genetics
Verified
Journal Article
Closed access
JOJames O'SUllivan
James O'SUllivan
CBCarolina C. Bitu
Carolina C. Bitu
SDSarah B. Daly
Sarah B. Daly
JUJill E. Urquhart
Jill E. Urquhart
MBMartin J. Barron
Martin J. Barron
MDMichael J. Dixon
Michael J. Dixon

9 June 2006 in Brain
Verified
Journal Article
Open access
PDF file
TTTanja Taivassalo
Tanja Taivassalo
JGJulie L. Gardner
Julie L. Gardner
RTRobert W. Taylor
Robert W. Taylor
ASAndrew M. Schaefer
Andrew M. Schaefer
JNJane Newman
Jane Newman
DTDouglass M. Turnbull
Douglass M. Turnbull
At present there are limited therapeutic interventions for patients with mitochondrial myopathies. Exercise training has been suggested as an approach to improve physical capacity and quality of life but it is uncertain whether it offers a safe and effective treatment for patients with heteroplasmic mitochondrial DNA (mtDNA) mutations. The objectives of this study were to assess the effects of exercise training and detraining in eight patients with single, large-scale mtDNA deletions to determine: (i) the efficacy and safety of endurance training (14 weeks) in this patient population; (ii) to determine the effect of more prolonged (total of 28 weeks) exercise training upon muscle and cardiovascular function and (iii) to evaluate the effect of discontinued training (14 weeks) upon muscle and cardiovascular function. Our results show that: (i) 14 weeks of exercise training significantly improved tolerance of submaximal exercise and peak capacity for work, oxygen utilization and skeletal muscle oxygen extraction with no change in the level of deleted mtDNA; (ii) continued training for an additional 14 weeks maintained these beneficial adaptations; (iii) the cessation of training (detraining) resulted in loss of physiological adaptation to baseline capacity with no overall change in mutation load. Patients' self assessment of quality of life as measured by the SF-36 questionnaire improved with training and declined with detraining. Whilst our findings of beneficial effects of training on physiological outcome and quality of life without increases in the percentage of deleted mtDNA are encouraging, we did not observe changes in mtDNA copy number. Therefore there remains a need for longer term studies to confirm that endurance exercise is a safe and effective treatment for patients with mitochondrial myopathies. The effects of detraining clearly implicate physical inactivity as an important mechanism in reducing exercise capacity and quality of life in patients with mitochondrial myopathy.

1 April 2004 in Neuromuscular Disorders
Verified
Journal Article
Closed access
RTRobert W. Taylor
Robert W. Taylor
ASAndrew M. Schaefer
Andrew M. Schaefer
MBMartin J. Barron
Martin J. Barron
RMRobert McFarland
Robert McFarland
DTDouglass M. Turnbull
Douglass M. Turnbull